Monica Roth

Prof. Monica Roth

Department of Pharmacology, Robert Wood Johnson Medical School, Piscataway, NJ, USA
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2014 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
SASriram Aiyer
Sriram Aiyer
GSG.V.T. Swapna
G.V.T. Swapna
NMNirav Malani
Nirav Malani
JAJames M. Aramini
James M. Aramini
WSWilliam M. Schneider
William M. Schneider
MRMonica Roth
Monica Roth
We report alterations to the murine leukemia virus (MLV) integrase (IN) protein that successfully result in decreasing its integration frequency at transcription start sites and CpG islands, thereby reducing the potential for insertional activation. The host bromo and extraterminal (BET) proteins Brd2, 3 and 4 interact with the MLV IN protein primarily through the BET protein ET domain. Using solution NMR, protein interaction studies, and next generation sequencing, we show that the C-terminal tail peptide region of MLV IN is important for the interaction with BET proteins and that disruption of this interaction through truncation mutations affects the global targeting profile of MLV vectors. The use of the unstructured tails of gammaretroviral INs to direct association with complexes at active promoters parallels that used by histones and RNA polymerase II. Viruses bearing MLV IN C-terminal truncations can provide new avenues to improve the safety profile of gammaretroviral vectors for human gene therapy.

15 February 2021 in Structure
Verified
Journal Article
Closed access
SASriram Aiyer
Sriram Aiyer
GSG.V.T. Swapna
G.V.T. Swapna
LMLi-Chung Ma
Li-Chung Ma
GLGaohua Liu
Gaohua Liu
JHJingzhou Hao
Jingzhou Hao
MRMonica Roth
Monica Roth

29 March 2023 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
AMArup Mondal
Arup Mondal
GSG.V.T. Swapna
G.V.T. Swapna
MLMaria M. Lopez
Maria M. Lopez
LKLaura Klang
Laura Klang
JHJingzhou Hao
Jingzhou Hao
APAlberto Perez
Alberto Perez

12 May 2015 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
SASriram Aiyer
Sriram Aiyer
PRPaolo Rossi
Paolo Rossi
NMNirav Malani
Nirav Malani
WSWilliam M. Schneider
William M. Schneider
ACAshwin Chandar
Ashwin Chandar
MRMonica Roth
Monica Roth
Target-site selection by retroviral integrase (IN) proteins profoundly affects viral pathogenesis. We describe the solution nuclear magnetic resonance structure of the Moloney murine leukemia virus IN (M-MLV) C-terminal domain (CTD) and a structural homology model of the catalytic core domain (CCD). In solution, the isolated MLV IN CTD adopts an SH3 domain fold flanked by a C-terminal unstructured tail. We generated a concordant MLV IN CCD structural model using SWISS-MODEL, MMM-tree and I-TASSER. Using the X-ray crystal structure of the prototype foamy virus IN target capture complex together with our MLV domain structures, residues within the CCD α2 helical region and the CTD β1-β2 loop were predicted to bind target DNA. The role of these residues was analyzed in vivo through point mutants and motif interchanges. Viable viruses with substitutions at the IN CCD α2 helical region and the CTD β1-β2 loop were tested for effects on integration target site selection. Next-generation sequencing and analysis of integration target sequences indicate that the CCD α2 helical region, in particular P187, interacts with the sequences distal to the scissile bonds whereas the CTD β1-β2 loop binds to residues proximal to it. These findings validate our structural model and disclose IN-DNA interactions relevant to target site selection.

1 September 2014 in Biomaterials
Verified
Journal Article
Closed access
DWDai-Tze Wu
Dai-Tze Wu
MRMonica Roth
Monica Roth

15 December 2016 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
JBJonathon D. Brzezinski
Jonathon D. Brzezinski
RFRoland Felkner
Roland Felkner
AMApexa Modi
Apexa Modi
MLMengdan Liu
Mengdan Liu
MRMonica Roth
Monica Roth
The p12 protein of murine leukemia virus (MLV) Gag is associated with the preintegration complex (PIC), and mutants of p12 (PM14) exhibit defects in nuclear entry/retention. Mutants of the phosphorylated serine 61 also have been reported to have defects in the early life cycle. Here we show that a phosphorylated peptide motif derived from human papillomavirus 8 (HPV-8), the E2 hinge region including residues 240 to 255, can functionally replace the main phosphorylated motif of MLV p12 and can rescue the viral titer of a strain with the lethal p12-PM14 mutation. Complementation with the HPV-8 E2 hinge motif generated multiple second-site mutations in live viral passage assays. Additional p12 phosphorylation sites were detected, including the late domain of p12 (PPPY) as well as the late domain/protease cleavage site of matrix (LYPAL), by mass spectrometry and Western blotting. Chromatin binding of p12-green fluorescent protein (GFP) fusion protein and functional complementation of p12-PM14 occurred in a manner independent of the E2 hinge region phosphorylation. Replacement of serine 61 by alanine within the minimal tethering domain ( 61 SPMASRLRGRR 71 ) maintained tethering, but in the context of the full-length p12, mutants with substitutions in S61 remained untethered and lost infectivity, indicating phosphorylation of p12 serine 61 functions to temporally regulate early and late p12 functions. IMPORTANCE The p12 protein, required for both early and late viral functions, is the predominant phosphorylated viral protein of Moloney MLV and is required for virus viability. Our studies indicate that the N terminus of p12 represses the early function of the chromatin binding domain and that deletion of the N terminus activates chromatin binding in the wild-type Moloney MLV p12 protein. Mass spectrometry and mutagenesis studies suggest that phosphorylation of both the repression domain and the chromatin binding domain acts to temporally regulate this process at the appropriate stages during infection.